Skip to main content

Table 3 Frequencies of benzodiazepine use in participants

From: Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial

  Baselinea Week 1 Week 2 Week 6 Week 12 Week 24
Mirtazapine n = 20 n = 17 n = 15 n = 14 n = 9 n = 8
Non-use, n (%)   8 (47.1) 7 (46.7) 11 (78.6) 8 (88.9) 7 (87.5)
1–6 days per week, n (%)   5 (29.4) 4 (26.7) 1 (7.1) 0 (0.0) 0 (0.0)
Every day, n (%)   4 (23.5) 4 (26.7) 2 (14.3) 1 (11.1) 1 (12.5)
SSRIs n = 45 n = 43 n = 42 n = 33 n = 28 n = 22
Non-use, n (%)   12 (27.9) 14 (33.3) 6 (18.2) 4 (14.3) 4 (18.2)
1–6 days per week, n (%)   15 (34.9) 8 (19.0) 12 (36.4) 9 (32.1) 4 (18.2)
Every day, n (%)   16 (37.2) 20 (47.6) 15 (45.5) 15 (53.6) 14 (63.6)
Sertraline n = 28 n = 26 n = 26 n = 22 n = 19 n = 15
Non-use, n (%)   7 (26.9) 9 (34.6) 5 (22.7) 3 (15.8) 3 (20.0)
1–6 days per week, n (%)   8 (30.8) 4 (15.4) 7 (31.8) 5 (26.3) 2 (13.3)
Every day, n (%)   11 (42.3) 13 (50.0) 10 (45.5) 11 (57.9) 10 (66.7)
Paroxetine n = 17 n = 17 n = 16 n = 11 n = 9 n = 7
Non-use, n (%)   5 (29.4) 5 (31.3) 1 (9.1) 1 (11.1) 1 (14.3)
1–6 day per week, n (%)   7 (41.2) 4 (25.0) 5 (45.5) 4 (44.4) 2 (28.6)
Every day, n (%)   5 (29.4) 7 (43.8) 5 (45.5) 4 (44.4) 4 (57.1)
  1. SSRI selective serotonin reuptake inhibitor
  2. aPatients prescribed benzodiazepines at baseline (day 1) were only counted in numbers in this table